Review highlights complexities in immunotherapy response for mycosis fungoides, suggesting insights from melanoma may enhance evaluation.
Key Points
This review reveals the intricacies of objectively assessing immunotherapy response in mycosis fungoides, emphasizing the need for better technologies.
The paper discusses the inability to uniformly distinguish reactive lymphocytes from malignant ones during treatment using current methods.
Assessment utilizes emerging histological technologies like multispectral imaging and spatial transcriptomics to better understand the tumor microenvironment.
The findings suggest that knowledge from melanoma research could significantly refine and improve the methodologies for evaluating immunotherapy in MF.